Jazz puts three programs on hold

Just days after seeing its badly battered stock price pick up on positive late-stage data from its fibromyalgia program, Jazz Pharmaceuticals told Reuters it's putting three of its programs on hold as it works out interest payments to bond holders. Jazz didn't make a fourth-quarter interest payment owed on $119 million in notes. "The interest issue has been the biggest overhang for our company and we continue to be in discussions with our senior secured note-holders to try to resolve that," Executive Director of Corporate Development Willie Quinn told Reuters. Report

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…